Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 7Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Lymphatic Metastasis 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × encorafenib × Clear all
NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Pfizer

Phase 1/2 Terminated
34 enrolled 44 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡